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Abstract
Background: Type 2 diabetes mellitus is one of the most common long-term conditions, and costs health services approximately
10% of their total budget. Active self-management by patients improves outcomes and reduces health service costs. While the
existing evidence suggested that uptake of self-management education was low, the development of internet-based technology
might improve the situation.
Objective: To establish the cost-effectiveness of a Web-based self-management program for people with type 2 diabetes
(HeLP-Diabetes) compared to usual care.
Methods: An incremental cost-effectiveness analysis was conducted, from a National Health Service and personal and social
services perspective, based on data collected from a multi-center, two-arm individually randomized controlled trial over 12
months. Adults aged 18 or over with a diagnosis of type 2 diabetes and registered with the 21 participating general practices
(primary care) in England, UK, were approached. People who were unable to provide informed consent or to use the intervention,
terminally ill, or currently participating in a trial of an alternative self-management intervention, were excluded. The participants
were then randomized to either usual care plus HeLP-Diabetes, an interactive, theoretically-informed Web-based self-management
program, or to usual care plus access to a comparator website containing basic information only. The participants’ intervention
costs and wider health care resource use were collected as well as two health-related quality of life measures: the Problem Areas
in Diabetes (PAID) Scale and EQ-5D-3L. EQ-5D-3L was then used to calculate quality-adjusted life years (QALYs). The primary
analysis was based on intention-to-treat, using multiple imputation to handle the missing data.
Results: In total, 374 participants were randomized, with 185 in the intervention group and 189 in the control group. The primary
analysis showed incremental cost-effectiveness ratios of £58 (95% CI –411 to 587) per unit improvement on PAID scale and
£5550 (95% CI –21,077 to 52,356) per QALY gained by HeLP-Diabetes, compared to the control. The complete case analysis
showed less cost-effectiveness and higher uncertainty with incremental cost-effectiveness ratios of £116 (95% CI –1299 to 1690)
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per unit improvement on PAID scale and £18,500 (95% CI –203,949 to 190,267) per QALY. The cost-effectiveness acceptability
curve showed an 87% probability of cost-effectiveness at £20,000 per QALY willingness-to-pay threshold. The one-way sensitivity
analyses estimated 363 users would be needed to use the intervention for it to become less costly than usual care.
Conclusions: Facilitated access to HeLP-Diabetes is cost-effective, compared to usual care, under the recommended threshold
of £20,000 to £30,000 per QALY by National Institute of Health and Care Excellence.
Trial Registration: International Standard Randomized Controlled Trial Number (ISRCTN) 02123133;
http://www.controlled-trials.com/ISRCTN02123133 (Archived by WebCite at http://www.webcitation.org/6zqjhmn00)
(J Med Internet Res 2018;20(6):e201)   doi:10.2196/jmir.9256
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Introduction
Background
There is a global epidemic of diabetes mellitus, with an
estimated 10% of the global population, or 422 million people,
affected. Around 90% of these people have type 2 diabetes
mellitus (T2DM) [1]. The personal and health care costs of
T2DM are substantial. Recent estimates suggest that about 11%
of the total global health expenditure is due to diabetes [2]. Most
of these costs are due to preventable complications [3]. Also,
diabetes also results in societal costs, including the cost of
missed workdays [4], personal costs, including out of pocket
costs [2], and the impact on employment and earnings potential
[5,6]. Patient education and self-management support has been
identified as a priority for global health in recent years [7] and
has the potential to both improve outcomes and reduce costs
[8]. However, internationally, uptake of self-management
education remains low [9], partly due to logistical problems
with attending courses [10].
Web-based self-management support has the potential to
increase uptake by overcoming some of the logistical problems
associated with other forms of delivery as it can be accessed at
home, at the user’s convenience. We have developed a
comprehensive, evidence-based, theoretically informed,
Web-based self-management program for adults with T2DM
called Healthy Living for People with Type 2 Diabetes
(HeLP-Diabetes). Overall content was guided by the Corbin
and Strauss model, which hypothesizes that patients must
undertake medical, emotional and role management in dealing
with a long-term condition [11]. If effective, Web-based
interventions have the potential to be highly cost-effective, as
they can be delivered at scale across large populations, with
relatively low additional costs per additional user [12], unlike
telephone-based or face-to-face education where labor costs
account for a substantial proportion of total cost [13].
We undertook an individually randomized controlled trial in
primary care to determine the effectiveness and
cost-effectiveness of HeLP-Diabetes compared to a simple,
text-based website, all with the access to usual care for people
with T2DM [14]. The aim of this paper is to present the health
economic analysis of this comparison based on the data collected
in the trial and to examine the cost-effectiveness of facilitated
access to HeLP-Diabetes. The analysis was undertaken from
the collective perspective of the National Health Services (NHS)
and personal social services (PSS), following the National
Institute of Health and Care Excellence (NICE) guidance [15],
as the two share the same resources. The results on clinical
effectiveness are reported in a separate article previously
published [16]. All costs are presented in pounds sterling (£)
2014 prices.
Methods
Approval and Ethical Considerations
Ethics approval was obtained from Camden and Islington
National Research Ethics Service (NRES) committee, reference
12/LO/1571.
Design, Setting, and Participants
The HeLP-Diabetes trial was a multi-center, two-arm
individually randomized controlled trial carried out in primary
care settings in England, United Kingdom (UK). The detailed
trial design was fully reported in the published protocol [14],
and the clinical effectiveness article [16]. There were no changes
to the methods after the protocol was agreed and the start of the
trial. Twenty-one general practices from across England
participated, with a mix of urban, suburban, and rural practices.
Adults, aged 18 years or over, registered with participating
practices, and diagnosed with T2DM were eligible for inclusion
in the trial. People who were unable to provide informed consent
(eg, due to psychosis or cognitive impairment), unable to use
the intervention (eg, due to physical, sensory or intellectual
impairment, or inability to understand basic spoken or written
English), terminally ill, or currently participating in a trial of
an alternative self-management intervention, were excluded.
There were no exclusions based on the duration of diagnosis,
level of diabetes control, previous experience of
self-management education, computer and internet experience,
or access to the internet at home.
Eligible participants were briefed on the trial by a practice or
research nurse (See the Patient Information Sheet in Multimedia
Appendix 1) and then individually randomized to either the
intervention or control group using Web-based randomization
independently of the trial team. Randomization was conducted
in a 1:1 ratio using random permuted blocks of sizes 2, 4, and
6, stratified by recruitment center. Participants were informed
the trial compared two forms of Web-based support but were
blinded as which was the intervention and which the comparator.
Each participant had access to their allocated intervention for
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12 months after randomization. Follow-up was undertaken at
3 and 12 months postrandomization.
Intervention
The intervention consisted of facilitated access to
HeLP-Diabetes. Facilitation consisted of an introductory training
session with practice nurses. In this session, patients were shown
on a computer how to log on and set a username and password,
and introduced to the structure, contents, and features of the
website and how to navigate it. A booklet summarizing the
information introduced in the session was given to the patients
to take home.
HeLP-Diabetes was a theoretically informed, Web-based
program, whose overall goals were to improve health outcomes
and reduce diabetes-related distress [17]. It was developed using
participatory design principles, with substantial input from
patients with T2DM and health professionals caring for such
patients. The content was designed to be accessible to people
with a wide range of literacy and health literacy skills, with all
essential content provided in both video and text. The content
sections covered information on diabetes as a medical condition
and its impact on people’s life; behavior change components to
support adoption of healthier lifestyles; and a third strand of
components focusing on emotional well-being based on
cognitive behavioral therapy and mindfulness.
The program also included an online forum where the
participants could post and share their questions, concerns, and
experiences. There was also an “Ask the Expert” facility, where
questions were reviewed and responded to by a
multi-disciplinary team including an information scientist,
clinicians, and patient representatives (see Multimedia Appendix
2). The forum was monitored daily by both research staff and
patient representatives.
Engagement with the program was promoted through regular
newsletters, emails and mobile text messages containing updates
on latest diabetes-related research or practice,
seasonally-relevant advice, and links to specific relevant parts
of the program. A medical information scientist reviewed the
diabetes-related research published each month and provided a
summary of the important, useful or relevant research. The
summary was then discussed by a team of clinicians,
psychologists, health service researchers and patient
representatives before selected items of interest were written
up for a patient audience. A more detailed description of the
intervention is provided in a separate clinical article [16] and a
National Institute for Health Research (NIHR) monograph [18].
Comparator
HeLP-Diabetes was designed to be provided as an addition to
current practice. However, to improve acceptability to
participants and to maintain blinding, all participants were
assigned access to a website. Participants in the control group
were given access to a simple information website, based on
the information readily available in the public domain on the
website of the main UK diabetes charity (Diabetes UK) or
National Health Service patient information website (NHS
Choices). Participants in the control group were also given an
introductory facilitation meeting, in which they were shown
how to navigate the website, and an information booklet to take
home.
Health Outcomes
The health outcomes for the health economic analysis were
diabetes-related distress, measured by the Problem Areas in
Diabetes (PAID) questionnaire, and quality of life, measured
by EQ-5D-3L. The PAID questionnaire consisted of 20 items
focusing on areas that cause difficulty for people living with
diabetes, including social situations, food, friends and family,
diabetes treatment, relationships with health care professionals
and social support [19]. PAID scores range from 0-100, with
lower scores indicating less stress, with a score of 40 or more
indicating significant distress. EQ-5D-3L is a standardized
instrument for measuring health-related quality of life, which
has five domains (5D), each with three levels (3L) measuring
daily difficulties in that domain [20]. Both these self-reported
outcome measures were collected online at baseline, three
months, and 12 months follow-up. The tariff for each
combination of the EQ-5D-3L levels for the UK population was
applied to calculate utility values [21]. The utility values range
from –0.594 to 1, with higher values indicating better quality
of life. Quality-adjusted life years (QALYs) were then calculated
over the duration of the trial using the area under the curve of
utility values from the three time points [22]. QALYs were not
discounted because the assessing period was 12 months.
Costs of the Intervention
There were two types of costs related to the intervention: those
incurred during the development and optimization of the
intervention; and those related to ongoing delivery and
maintenance of the intervention. Development costs were not
taken into account for this analysis. As per NICE guidance [15],
the evidence on costs should relate to the National Health
Services (NHS) and personal social services (PSS) resources.
The development costs, in this case, although considerable,
related to research funding rather than NHS and PSS resources,
and unlikely to be repeated if the intervention is adopted in
practice.
The costs relating to ongoing maintenance and delivery of the
intervention within the trial form the basis for the current
analysis. These consisted of: the cost of delivery of the
intervention; the cost of maintenance and updating of the
intervention; and cost of facilitating activities undertaken to
improve uptake and use. If the intervention were to be widely
implemented into routine health care, all these activities would
be required on an on-going basis. Therefore, the costs of these
activities that occurred during the trial were used to estimate
the real costs in practice.
Delivering, maintaining, and updating the intervention involved
two types of costs: costs related to hardware and software; and
staff costs. Staff costs related to activities for engagement,
moderating the online forum, revising the content of the website,
and responding to ‘Ask the Expert’ questions. Staff costs were
also incurred by the third-party service provider responsible for
hosting and maintaining the intervention.
Costs related to hardware, software, and work undertaken by
the third-party service provider were recorded from actual
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invoices. These included a weekly review of recent development
in the field, domain names purchase, website hosting, quarterly
maintenance of the website, and Security Socket Layer
certificate purchase. Some of the third-party services were
contracted for longer than 12 months, so costs were calculated
for a one-year period based on the invoiced amount and their
length of service.
Activities not undertaken by the third-party providers were
carried out by either professional staff or by patient
representatives. Costs related to work undertaken by patient
representatives were recorded from the payments made to
representatives, who were reimbursed for their time in line with
INVOLVE guidance [23]. INVOLVE is a NIHR funded national
advisory group to support active public involvement in NHS,
public health and social care research. These included patient
representatives’ feedback on development review, forum
monitoring, and their review of feedback from the clinical team.
Costs related to activities undertaken by research staff and
clinicians were estimated from workloads during the trial period,
by recording the time taken for each activity, the frequency of
that activity and the number and grade of staff involved. These
included writing and sending emails, short message service
(SMS), and newsletters, forum monitoring, interaction with
patients on the website, and contents review and update. The
costs were then calculated by multiplying the time spent by the
average wage for each type of staff member. Hourly costs for
research staff were taken from the academic pay scale [24], and
hourly costs for General Practitioners (GPs) were taken from
unit costs of health and social care edited by Personal Social
Services Research Unit (PSSRU) [25].
Participants in both groups were provided with facilitation by
practice or research nurses to encourage use and uptake of the
intervention and comparator. Participants were also provided
with a booklet, summarizing the training they had received
(login details, how to use the website). All participants were
provided with this introductory session and booklet. As this
activity was not required for the comparator website and was
only undertaken to maximize comparability between the
intervention and the comparator, we considered it a research
activity and assumed that no intervention costs were incurred
in the control group.
Practice/research nurses required training in providing this
introductory session. Each nurse attended an hour face-to-face
training session provided by a member of the research team.
They were also provided with printed training materials,
reminding them how to register patients and how to introduce
the website. The costs of the training and introductory session
were calculated from the time spent on each activity by the
nurses and research team staff, plus travel time for the research
team, multiplied by their respective hourly salary rates. In this
case, we took the hourly rate of practice nurses for all nurses’
time. The costs of the printed training materials and the booklets
issued to participants were obtained from invoices from the
printers.
All intervention costs were allocated to the participants in the
intervention group of the trial to give a per participant cost.
Health Service Resource Use
Health care resource use, including primary, secondary and
community services, was collected for both groups using
bespoke service use questionnaires. The majority of information
about service use and participants’ prescriptions were extracted
from participants’ medical records by practice or research
nurses. The remainder of the service use data were collected
retrospectively from participants using a self-report
questionnaire online. These data were collected at baseline for
the 12 months period before the trial, at three months follow-up
for the three months period after randomization and at 12 months
follow-up for the nine months after three months follow-up.
The quantities were then multiplied by a set of national average
unit costs (Table 1). The total costs of health services were then
summarised at an aggregated level, (ie, costs of health services
use from data provided by nurses, medication costs from data
provided by nurses, and costs of health and social services use
from data provided by participants), for the corresponding
periods respectively. Any missing data on individual services
resulted in a missing cost for the entire section.
Where applicable, Value Added Tax at 20%, salary on-costs,
and overheads were added. Unit costs for out-of-hours services
were estimated based on a national audit [26], assuming the
duration of consultations was the same as for in-hours services.
Data on travel time for home visits were not available, so we
adopted the assumed 12 minutes per visit estimate made by
PSSRU 2014 [25]. No allowance was made for travel expenses.
Due to the large amount of medications taken by this particular
population, only current prescriptions taken at the time of data
collection were extracted. Prescribed items were matched with
the Prescription Cost Analysis England 2014 [28] for a cost per
item, using their generic name, form, and strength where
available. In the absence of full information, a weighted average
cost per item was calculated based on available information.
Unless it was specified that no medication was prescribed, blank
entries were considered as missing data. We also assumed that
all prescriptions were for chronic conditions and issued for one
month at a time over the corresponding period. Costs were not
discounted as the assessing period was 12 months.
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Table 1. National average unit cost used in the analysis.
SourcesUnit cost (£)
(per consultation or per episode)
Health Service Use
GPa consultation
PSSRUb 2014 [25]38In surgery
PSSRU 2014 [25]62Home visit
PSSRU 2014 [25]23Telephone
Practice nurse consultation
PSSRU 2014 [25)11In surgery
PSSRU 2014 [25]18Home visit
PSSRU 2014 [25]56NHSc Walk-In Clinic
Out-of-hour services
Out-of-hours GP services in England [26], PSSRU 2014 [25]36Telephone advice
Out-of-hours GP services in England [26], PSSRU 2014 [25]117Home visit
Out-of-hours GP services in England [26], PSSRU 2014 [25]86In surgery
Reference Costs 2013-14 [27]167Accident and emergency service
admission
Reference Costs 2013-14 [27]44Podiatrist
Reference Costs 2013-14 [27]97Optometry
Reference Costs 2013-14 [27]46Physiotherapy
Counselling
PSSRU 2014 [25]46Primary care
Reference Costs 2013-14 [27]138Community
Reference Costs 2013-14 [27]2Clinical test
Reference Costs 2013-14 [27]111Outpatient appointment
Reference Costs 2013-14 [27]698Day case
Reference Costs 2013-14 [27]1891Inpatient admission
District nurse
Reference Costs 2013-14 [27], PSSRU 2014 [25]46Home visit
Reference Costs 2013-14 [27]37In surgery or clinic
PSSRU 2014 [25]55Social worker
Reference Costs 2013-14 [27]64Occupational therapy
Reference Costs 2013-14 [27]80Dietician
aGP: general practitioner.
bPSSRU: Personal Social Services Research Unit.
cNHS: National Health Service.
Analysis
Missing Data
Multiple imputation was used as the primary method to account
for missing data at both baseline and follow-up. A chained
equation model was developed, and predictive mean matching
was used as the imputation method for continuous variables,
using the five nearest neighbors to the prediction as a set to
draw from. All missing data were imputed separately by trial
group. The imputation was performed at the aggregated level
(ie, costs of health services use from data provided by nurses,
prescription costs from data provided by nurses, costs of health
and social services use from data provided by participants, PAID
score and EQ-5D-3L utility value from data provided by
participants). PAID and EQ-5D-3L data collected outside of
the pre-specified “window” of 10-14 months following
randomization were considered invalid as 12-month outcomes
and only used as imputing factors along with baseline and other
outcome data. The percentage of missing data served as the base
of the number of imputations, as a rule of thumb [29].
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Primary Analysis
The primary analysis followed a pre-specified analysis plan,
comparing the groups as randomized (intention-to-treat). It
focused on a within-trial analysis of costs and benefits, with no
projected time horizon. A linear mixed effects model was fitted
with the 12-month outcome as the dependent variable, adjusting
for the baseline variables age, sex, presence of pre-existing
cardiovascular disease, duration of diabetes, smoking status and
corresponding baseline outcome (costs over 12 months before
baseline, PAID score at baseline and EQ-5D-3L utility value at
baseline, respectively) as fixed effect terms. Center effects were
included as random-effects in the analysis. No time-dependent
terms, interaction terms or effect modifiers were used. The
difference in mean 12-month costs and outcomes were estimated
based on the model. Incremental cost-effectiveness ratios (ICER)
were calculated by dividing the difference in mean cost by the
difference in mean health outcome. The resulting incremental
cost per QALY gained was then compared against the
recommended willingness-to-pay (WTP) threshold of
£20,000-£30,000 per QALY by NICE [15].
A non-parametric bootstrap technique was employed to explore
the uncertainty of point estimates of the difference in mean
12-month costs and outcomes from primary analyses. Five
thousand bootstrapped datasets were created and the total costs
and outcome estimated for each one. The results from bootstrap
resampling were used to construct 95% CI for incremental costs,
incremental PAID score, incremental QALYs, and to plot the
cost-effectiveness plane and cost-effectiveness acceptability
curve to show the uncertainty surrounding the primary results
[30].
Sensitivity Analyses
Complete case analysis was undertaken to assess the
performance of the imputation model compared to a complete
case analysis that assumes data were missing completely at
random.
The intervention cost per user estimated in the primary analysis
was based on the number of trial participants, which would be
unrealistic if the intervention were to be implemented more
widely. We, therefore, undertook a one-way sensitivity analysis,
exploring the cost per user as numbers of users increased.
The cost of nurse-led facilitation is per participant, so will be
incurred by each registered user, regardless of the total number.
Each practice referring patients to the intervention needed at
least one nurse who is trained in the facilitating activities. In
this trial, each practice or research nurse only undertook to
facilitate activities for up to 10 patients, whereas practices are
likely to have several hundred patients with T2DM who could
be registered, which would reduce the per-user cost of training
nurses to register patients. However, taking into consideration
staff turnover and the possibility of multiple staff being trained,
we made the conservative assumption that the costs of training
practice staff would remain the same per user.
The costs of maintaining and delivering the intervention remain
the same up to the total capacity of the current server (which is
for 10,000 active users). This means that the average cost per
user reduces up to 10,000 active users. The one-way sensitivity
analysis, therefore, explored the change in intervention cost per
user about the ICER on the implicit assumption that the impact
on health services use, and QALYs in the trial was generalizable.
Because the national WTP threshold is only expressed regarding
incremental cost per QALY, the one-way sensitivity analysis
was not undertaken for the incremental PAID score.
All analyses were undertaken using STATA SE 14.2 software.
Results
Participants in the Study
Recruitment took place between September 2013 and December
2014. Of 374 participants randomized, 185 were allocated to
the intervention and 189 to the control group. The average age
at randomization was 64.9 (SD 9.5) years old in the intervention
group and 64.7 (SD 9.1) years old in the control group. There
were four participants missing time since diagnosis of diabetes,
two in each group. Among the participants with this information,
the mean duration was 7.8 (SD 5.7) years in the intervention
group and 8.2 (SD 6.1) years in the control group. The
proportion of male participants in the intervention group
(127/185, 69%) was similar to that in the control group (131/189,
69%). Further description of the participants’ characteristics
can be found in the clinical effectiveness article [16].
Missing Data
In the intervention group, there were 143/185 (77%) participants
who completed the three months self-report questionnaire and
129/189 (70%) participants who completed the 12 months one.
In the control group, there were 152/189 (80%) participants
who completed the three months questionnaire and 135/189
(71%) participants who completed the 12 months questionnaire.
The difference in completion rate was not significant (Pearson’s
chi-squared test P=.459 at 3 months, P=.718 at 12 months).
There were rare cases where participants completed the
questionnaire with one or two items missing (see Multimedia
Appendix 3). In general, the missing data on self-report were
due to not responding. The percentage of missing data was low
and did not exceed 30% for any variable. The number of
imputations was therefore set to 30.
Intervention Costs
Maintenance and Delivery
Staff costs of maintenance and delivery of the intervention were
estimated to be £18,783 a year, including patient representatives’
feedback work (Table 2). The total infrastructure cost per year
was estimated at £23,013, including £93 for 10 domain names,
£3600 for website hosting, £19,200 for maintenance, and £120
for Security Socket Layer Certificate. The two parts gave a total
operating cost of HeLP-Diabetes per year of £41,796. Allocating
these costs to the 185 participants in the intervention group, the
average cost per participant was £226.
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Table 2. Staff costs of maintenance and delivery of HeLP-Diabetes.
Cost (£) per yearUnit cost (£) per hourPayment scale or
method
IntensityActivities
667534Grade 6 staff1 day/2 weeksEmails, newsletters, SMSa
156030Fixed contract1 hour/weekLibrarian review of recent develop-
ment
46818Cash payment30 minutes/person, 2 persons/2
weeks
Patient representatives feedback on
librarian’s review
46818Cash payment30 minutes/person, 2 persons/2
weeks
Forum monitoring by patient repre-
sentatives
89034Grade 6 staff1 hour/2 weeksForum monitoring by staff
605121GP1 hour/time, 5 times/yearClinical team website interaction
4518Cash payment15 minutes/person, 2 persons/time,
5 times/year
Patient representatives review feed-
back from clinical team
178034Grade 6 staff2 hours/2 weeksContent checking, revising and up-
dating by staff
6292121GP2 hours/2 weeksContent checking, revising and up-
dating by clinical team
18,783Total
aSMS: short message service.
Facilitating Activities
The costs of training the nurses to undertake the facilitation,
including both the costs of the research staff providing the
training and the costs of the nurses being trained, came to £3785
across all practices involved in the trial. The cost of the printed
training materials was £78. Thus, the total training costs in the
trial were £3863, or £21 per participant in the intervention group.
The time allocated to registering participants and introducing
them to the intervention was 20 minutes per participant, hence
cost one-third of a practice nurse’s hourly consultation rate
(£44) [25]. The cost of the booklet given to each participant in
the intervention group was £0.95 per booklet.
The total intervention cost was, therefore, £263 per participant,
made up of £226 costs of maintenance and delivery; £21 for
initial training of practice/research nurses; and £16 for nurse-led
facilitation. We assumed zero costs for the comparator, as
although we incurred costs during the trial, these would not
have been incurred outside of a trial.
Primary Analysis
The outcomes and the incremental cost and effectiveness of the
primary analysis are presented in Table 3. The mean costs of
health resources use in the 12 months trial period were higher
in the control group than in the intervention group (for detailed
health resources use, see Multimedia Appendix 3). The
unadjusted difference in mean total costs was £12, with a lower
value in the control group. When adjusted for baseline health
resource use 12 months before the trial, the mean total costs in
the intervention group were £131 (SE £169) higher than the
control group. After further adjusting for baseline variables (ie,
age, sex, history of cardiovascular diseases, smoking status,
time since diabetes diagnosis), the difference was reduced to
£111 (95% CI –156 to 362).
The mean PAID score was higher in the control group than the
intervention group throughout the trial. The unadjusted
difference in PAID score at 12 months was 3.1, with a lower
score in the intervention group. After adjusting for baseline
PAID score, the mean PAID score was 1.9 (SE 1.3) lower in
the intervention group than the control group. This remained
similar when further adjusting for other baseline variables (ie,
age, sex, history of cardiovascular diseases, smoking status,
time since diabetes diagnosis).
Mean EQ-5D-3L utility in both groups increased at three months
from baseline. At 12 months, the mean utility value fell in both
groups, but the fall was greater in the control group. Regarding
QALYs, during the 12-month trial period, the intervention group
had a mean QALY of 0.802 (SE 0.016) compared with 0.764
(SE 0.023) in the control group, giving an unadjusted difference
of 0.038. After adjusting for EQ-5D-3L utility values at baseline
and other baseline variables (ie, age, sex, history of
cardiovascular diseases, smoking status, time since diabetes
diagnosis), the incremental QALY was 0.020 (95% CI –0.001
to 0.044), comparing the intervention group to the control group.
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Table 3. Incremental cost-effectiveness analysis based on imputed data, by randomized group.
Control (n=189)Intervention (n=185)Outcomes
Costs (£)
0263Intervention cost, mean
2067 (144)1816 (125)Health resources use in the 12 months trial perioda, mean (SE)
2067 (144)2079 (125)Total cost during trial period, mean (SE)
N/Ac111 (–156 to 362)bIncremental cost for intervention group, adjusted for health resources use cost at
baseline and other baseline variables, mean (95% CI)
HRQoLd
19.9 (1.4)18.1 (1.3)Baseline PAIDe, mean (SE)
17.3 (1.3)15.7 (1.2)Three months PAID, mean (SE)
17.6 (1.4)14.5 (1.2)Twelve months PAID, mean (SE)
N/A–1.9 (–4.2 to 0.4)bIncremental PAID score at 12 months for intervention group, adjusted for baseline
PAID score and other baseline variables, mean (95% CI)
0.766 (0.021)0.793 (0.018)Baseline EQ-5D-3L utilityf, mean (SE)
0.786 (0.024)0.811 (0.016)Three months EQ-5D-3L utility, mean (SE)
0.736 (0.037)0.793 (0.023)Twelve months EQ-5D-3L utility, mean (SE)
0.764 (0.023)0.802 (0.016)QALYs in the 12 months trial periodg, mean (SE)
N/A0.020 (–0.001 to 0.044)bIncremental QALYs for intervention group, adjusted for baseline EQ-5D-3L utility
value and other baseline variables, mean (95% CI)
ICERh
N/A58 (–411 to 587)bIncremental cost (£) per unit improvement on PAID scale, mean (95% CI)
N/A5550 (–21,077 to 52,356)bIncremental cost (£) per QALY gained, mean (95% CI)
aThis was calculated based on the assumption that the medications were for chronic use and were prescribed monthly.
bBaseline variables included age, sex, history of cardiovascular diseases, smoking status, time since diabetes diagnosis.
cN/A: not applicable.
dHRQoL: health-related quality of life.
ePAID: Problem Areas in Diabetes.
fEQ-5D-3L: A descriptive system of health-related quality of life state.
gQALY: quality-adjusted life year.
hICER: fully adjusted incremental cost-effectiveness ratio.
Figure 1. Cost-effectiveness plane and cost-effectiveness acceptability curve comparing the intervention group to the control group.
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Incremental Cost-Effectiveness Analysis
The fully adjusted incremental cost-effectiveness ratio (ICER)
was £58 (95% CI –411 to 587) per unit improvement on PAID
scale, and £5550 (95% CI –21,077 to 52,356) per QALY gained,
comparing the intervention with the control (Table 3). For both
health outcomes, the ICERs indicated a costlier and more
effective intervention. Comparing with the recommended WTP
threshold for QALY, the intervention presented a much lower
ratio. The majority of the bootstrapped replicates fell in the
north-east corner of the cost-effectiveness plane, indicating a
costlier and more effective intervention (Figure 1). A lesser
proportion of the replicates fell in the south-east corner,
indicating a less costly but more effective intervention. A small
group (153/5,000, 3%) of the replicates fell on the left side of
the Y axis, indicating a less effective intervention. Overall, the
majority of bootstrapped replicates fell under the WTP
thresholds. The CEAC further demonstrated the conclusion was
likely to be robust with an 87% probability that the intervention
was cost-effective at a WTP threshold of £20,000 per QALY
and 92% at £30,000 per QALY (Figure 1).
Table 4. Comparison of outcomes between imputed data and complete cases.
ControlInterventionAnalysis
MeannMeann
Costs of health services use (£)
In the 12 months before recruitment
2084 (164)1891792 (126)185Imputed (SE)
1677 (1,418)1011793 (1,545)96Complete cases (SD)
In the 12 months trial period
2067 (144)1891816 (125)185Imputed (SE)
1721 (1,539)1011695 (1,404)96Complete cases (SD)
PAIDa scores
Baseline
19.9 (1.4)18918.1 (1.3)185Imputed (SE)
19.0 (16.5)10118.8 (16.8)96Complete cases (SD)
Twelve months
17.6 (1.4)18914.5 (1.2)185Imputed (SE)
15.9 (15.2)10114.6 (15.5)96Complete cases (SD)
EQ-5D-3Lb utility
Baseline
0.766 (0.021)1890.793 (0.018)185Imputed (SE)
0.829 (0.207)1010.792 (0.232)96Complete cases (SD)
Three months
0.786 (0.024)1890.811 (0.016)185Imputed (SE)
0.840 (0.229)1010.824 (0.186)96Complete cases (SD)
Twelve months
0.736 (0.037)1890.793 (0.023)185Imputed (SE)
0.825 (0.250)1010.814 (0.218)96Complete cases (SD)
aPAID: Problem Areas in Diabetes.
bEQ-5D-3L: A descriptive system of health-related quality of life state.
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Figure 2. One-way sensitivity analysis of ICER in relation to number of users.
Complete Case Analysis
A complete case analysis (CCA) was performed on 96/185
(52%) in the intervention group and 101/189 (53%) in the
control group who had complete data on baseline variables
required for adjustment, costs and the two health outcomes.
Comparing the results from CCA to the primary analysis, the
mean costs were lower in the CCA than in the primary analysis,
except for the mean costs in the 12 months before recruitment
in the intervention group (Table 4). Similarly, EQ-5D-3L utility
scores at all time points were higher in the CCA than in the
primary analysis, except for the score at baseline in the
intervention group. The results of the CCA showed a smaller
incremental outcomes (PAID –1.6, 95% CI –5.1 to 1.4 and
QALY 0.010, 95% CI –0.018 to 0.044) and bigger incremental
costs (£185, 95% CI –145 to 504), with higher variation
surrounding each estimate, in comparison with the primary
analysis. The ICER for a one unit improvement on PAID score
was £116 (95% CI –1299 to 1690). The intervention was still
cost-effective (ICER=£18,500/QALY, 95% CI -203,949 to
190,267), compared with the WTP threshold, but with a higher
level of uncertainty (probability of being cost-effective was
45% at £20,000 and 52% at £30,000).
One-Way Sensitivity Analysis for the Cost of
Intervention
Assuming the effectiveness and the impact on health resources
use remained the same, the ICER declined rapidly with
increasing numbers of users (Figure 2). Once there were 81
users, the ICER dropped to around £20,000/QALY. The ICER
became negative upon the intervention reaching 363 users,
thereafter dominating the control (ie, the intervention became
less costly and more effective than the control).
Figure 2. One-way sensitivity analysis of ICER in relation to
the number of users
Discussion
Principal Results
In this within-trial economic evaluation, we found that
HeLP-Diabetes plus usual care was highly likely to be
cost-effective, compared with free information-only websites,
such as that provided by NHS Choices or Diabetes UK, plus
usual care. The ICER in the primary analysis was estimated at
£5550 per QALY gained with 87% and 92% probability of
being cost-effective for WTP thresholds of £20,000 and £30,000
per QALY, respectively. Once there were over 363 users,
HeLP-Diabetes became dominant (ie, less costly and more
effective) compared to free information websites, on top of
usual care.
Strengths and Limitations
The strength of this study comes from the reliance on actual
data from a trial. We collected a wide range of information on
health and social service resource use, including community,
primary and secondary care. Most of the service use data came
from the GP electronic health care records, supplemented by
self-report data from participants for services not recorded in
the electronic notes. This approach reduced the potential bias
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coming from retrospective recall by participants. The
completeness of self-report sections was mostly secured by the
mandatory questionnaire procedure which prevented skipping
individual questions, therefore reduced missing data. Due to
the volume of medication taken in this population, however,
only the current medication at the time of data collection was
extracted, and the assumption was made that all medications
were for chronic use. This could overestimate medication costs,
but it should not introduce a bias towards either group. The
comparison between CCA and the primary analysis showed that
the imputation had a greater impact on the control group than
on the intervention group. The results suggested that the
participants who completed all tests and questionnaires were
likely to have a lower level of health services use and better
health.
We decided at the outset not to include the investment costs
incurred in the development of the intervention in our analysis.
This was because, being funded by research grants, these costs
were unlikely to re-occur if the intervention was widely
implemented by the NHS, therefore being irrelevant to the
decision maker for future planning. We used the running costs
occurred in the trial to estimate the operating costs in practice.
However, there may be more maintenance costs over a longer
period as technology changes, and there may be a need for
software updates. One example would be that adapting this
program to optimize user experience on a mobile phone screen
would incur additional programming costs. Neither PAID nor
QALYs are clinical outcomes, and their association with
outcomes such as glycated hemoglobin (HbA1c) is not always
straightforward. Although necessary for comparability with
other interventions, their clinical relevance is limited.
According to National Diabetes Audit 2016-17 [31], 56% of
registered T2DM patients are male, and 47% are under age 65
in England. While the mean age is similar, the proportion of
male patients in our study participants is higher. What impact
this might have on the overall effects of HeLP-Diabetes is
unknown at this point, but it is worth noting that many
face-to-face self-management interventions appear to appeal
more to women than men, so the gender imbalance in favour
of men seen in our trial may suggest that providing both
face-to-face and online self-management interventions may be
one way to reach both men and women [32]. Furthermore, the
participants in our study were well-managed in their condition
from the beginning, with mean HbA1c of 7.3% (56 mmol/mol)
at baseline. In a related point, the participants in our study had
a duration of diagnosis ranging from 0-34 years. However, the
effectiveness data from the trial showed that neither duration
of diabetes nor baseline HbA1c impacted on the overall change
in HbA1c [16].
Population impact of an intervention is a product of effect size,
reach and uptake–a highly efficacious intervention that is only
used by a very small proportion of the population may have less
impact than a less efficacious intervention which is widely used.
These trial data cannot give us an estimate of the eventual reach
and uptake of this intervention, as trial participants are known
to differ from the total population of patients who may be
targeted by an intervention [33]. In parallel with the trial
reported here, we undertook an implementation study to explore
issues around reach and uptake, along with factors which
impacted on these. These data will be reported separately.
A potential disadvantage of a rigorous evaluation is the time
and resource required. There may be questions about the value
of such investment in a rapidly evolving landscape where the
intervention in question may be rendered obsolete by the time
the evaluation is completed. However, while the digital
technology changes rapidly, the underlying principles do not.
Another potential limitation to consider is the importance of
taking into account the target population of the intervention. It
is possible that benefits will not scale across the population
equally. For instance, in 2017, 37% of the adults aged 65+ in
Great Britain read online newspapers or magazines, in contrast
to over 70% of the adults aged under 55, whilst 20% of adults
aged 65+ shared self-created content online, compared with
over 50% in the age groups under 55 [34]. Interventions that
have a wide target population will need to reflect the
heterogeneity in preferences of their target populations, and the
use and impact of the interventions may vary, affecting
cost-effectiveness.
Comparison with Prior Work
Although one of the major drivers for research into digital health
interventions, such as HeLP-Diabetes, is their expected
cost-effectiveness [12,35], there has been relatively little
published evidence. A Cochrane review of digital interventions
for alcohol consumption published in 2017 identified only 7/42
(16.7%) qualified studies reported economic evaluations [36].
Several systematic reviews of economic evaluations on mental
health-related digital interventions conducted in recent years
identified 5 studies for anxiety disorder [37], 16 articles for
mental health in general [38], and 12 studies for depression [39],
respectively. Other economic evaluations of digital health
interventions cover a wide range of target conditions, including
irritable bowel syndrome [40], substance misuse [41], weight
management [42], insomnia [43,44], eating disorders [45,46]
and postoperative recovery [47]. Results of these studies were
favourable regarding costs, especially when wider health care
or societal costs were taken into account but did not show a
significant impact on quality of life during follow-up periods.
Our results are therefore broadly in line with previous findings
and thus contribute to the growing but still insufficient evidence
pool of economic evaluation of digital interventions.
Conclusions
As there are 3.5 million people diagnosed with T2DM in Great
Britain in 2016 [48-50], and over 90% of the households have
internet access in 2017 [34], HeLP-Diabetes has the potential
of delivering an effective intervention on a wide scale with
negligible marginal costs. Although we do not expect
internet-based interventions to be suitable for everyone at the
moment, with the internet further permeating our daily life and
people adapting to the internet era, there is potential for digital
health interventions to help alleviate the burden of chronic
conditions on health care systems in the long run. Our findings
supported the cost-effectiveness of the intervention once taken
up by patients. Further research is needed on how digital health
interventions such as HeLP-Diabetes can be delivered and
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maintained in a sustainable and cost-effective manner, with the
focus on user experience outside of a study setting. The
successful realization of this effect might lie in identifying the
more susceptible user groups and engaging them at an optimal
time. More empirical studies are needed to help plan the
systematic incorporation of digital interventions in medical
practice.
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